Affordable Access

Access to the full text

Myrcene Attenuates Renal Inflammation and Oxidative Stress in the Adrenalectomized Rat Model

Authors
  • Islam, Azim Ullah Shamsul1, 2
  • Hellman, Björn2
  • Nyberg, Fred2
  • Amir, Naheed1
  • Jayaraj, Richard L.1
  • Petroianu, Georg
  • Adem, Abdu1,
  • 1 (R.L.J.)
  • 2 (F.N.)
Type
Published Article
Journal
Molecules
Publisher
MDPI AG
Publication Date
Sep 30, 2020
Volume
25
Issue
19
Identifiers
DOI: 10.3390/molecules25194492
PMID: 33007969
PMCID: PMC7582976
Source
PubMed Central
Keywords
License
Green

Abstract

Physiological Glucocorticoids are important regulators of the immune system. Pharmacological GCs are in widespread use to treat inflammatory diseases. Adrenalectomy (ADX) has been shown to exacerbate renal injury through inflammation and oxidative stress that results in renal impairment due to depletion of GCs. In this study, the effect of myrcene to attenuate renal inflammation and oxidative stress was evaluated in the adrenalectomized rat model. Rats were adrenalectomized bilaterally or the adrenals were not removed after surgery (sham). Myrcene (50 mg/kg body weight, orally) was administered post ADX. Myrcene treatment resulted in significant downregulation of pro-inflammatory cytokines (IL-1β, IL-6, and TNF-α) compared to untreated ADX rats. In addition, myrcene resulted in significant downregulation of immunomodulatory factors (IFNγ and NF-κB) and anti-inflammatory markers (IL-4 and IL-10) in treated ADX compared to untreated ADX. Myrcene significantly increased the antioxidant molecules (CAT, GSH, and SOD) and decreased MDA levels in treated ADX compared to untreated. Moreover, myrcene treatment reduced the expression of COX-2, iNOS, KIM-1, and kidney functional molecules (UREA, LDH, total protein, and creatinine) in ADX treated compared to ADX untreated. These results suggest that myrcene could be further developed as a therapeutic drug for treatment of kidney inflammation and injury.

Report this publication

Statistics

Seen <100 times